To report an adverse event or product quality issue, please email us at reportnow@argenx.com or call us at 1-833-274-9411.
©2026 argenx | Disclaimer | Privacy Policy | Regulations | U.S. Supplemental Privacy Notice
A First-in-Class Approach to FcRn
Adimanebart is a humanized monoclonal antibody designed to activate muscle-specific kinase (MuSK), a critical regulator of neuromuscular junction (NMJ) stability and function. Adimanebart is being evaluated for patients with congenital myasthenic syndromes (CMS) and spinal muscular atrophy (SMA).
Current argenx Pipeline Progress
No results
Publications
Explore the peer-reviewed publications behind the clinical development and outcomes of adimanebart and more in long-overlooked diseases.
Explore More
At argenx, every piece of the innovation story connects. See where it leads next.
ARGX-118
Designed around the first novel airway inflammation target identified in decades.
Empasiprubart
Engineered to block complement activation at C2, with potential across multiple severe autoimmune disease indications.
Partnered Program Success
See how IIP-born assets move forward with the right partners.
